Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells

Trastuzumab (Herceptin(®)), a humanized IgG1 antibody raised against the human epidermal growth factor receptor 2 (HER2/neu), is the main antibody in clinical use against breast cancer. Pre-clinical evidence and clinical studies indicate that trastuzumab employs several anti-tumour mechanisms that m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Karagiannis, Panagiotis, Singer, Josef, Hunt, James, Gan, Samuel K. E., Rudman, Sarah M., Mechtcheriakova, Diana, Knittelfelder, Regina, Daniels, Tracy R., Hobson, Philip S., Beavil, Andrew J., Spicer, James, Nestle, Frank O., Penichet, Manuel L., Gould, Hannah J., Jensen-Jarolim, Erika, Karagiannis, Sophia N.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3017872/
https://ncbi.nlm.nih.gov/pubmed/18941743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-008-0607-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars